This is a routine procedural win for Gilead on a de minimis individual claim. No material read-through for the broader Atripla/TDF litigation or Gilead's financials. Monitor the larger Holley MDL for any substantive rulings.
Price Chart
Executive Summary
A federal district court dismissed with prejudice all claims by pro se plaintiff Diana Cash against Gilead Sciences, finding her amended complaint still failed to state a plausible claim for relief after multiple prior opportunities to amend. The ruling eliminates a trivial, individual product-liability case with no material financial exposure for Gilead.
Court Ruling Details
Key Facts
- The court granted Gilead's motion to dismiss plaintiff Diana Cash's claims with prejudice.
- Cash alleged side effects from Gilead's medication Atripla but failed to articulate any legal theory or cause of action.
- The dismissal is without leave to amend, ending the case for this plaintiff.
- The case was part of a multi-plaintiff litigation (Holley v. Gilead) but involved only one individual pro se plaintiff seeking a total of $25,000 in damages.
- The court also denied as moot Gilead's motion to suspend case deadlines.
Financial Impact
Plaintiff sought $25,000 in damages — immaterial relative to Gilead's market cap (~$80B+).
Risk Factors
- No material risk — the dismissed claim was trivial and individual.
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-d08fc1cf14-GILD |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Institutional Cluster | $156.04 | awaiting T+5 | — | $158.69 (−1.70%) |
Oct 16, 2026 10d ago | Insider Cluster | $153.07 $158.69 | ▲ +3.67% | ▲ +3.82% | $158.69 (+3.67%) |
Oct 14, 2026 13d ago | Court Ruling | $157.37 $157.19 | ▼ −0.11% | ▲ +0.90% | $158.69 (+0.84%) |
Sep 16, 2026 5w ago | Insider Cluster | $150.89 $149.69 | ▼ −0.80% | ▼ −1.40% | $158.69 (+5.17%) |
Sep 16, 2026 5w ago | Insider Cluster | $150.89 $149.69 | ▼ −0.80% | ▼ −1.65% | $158.69 (+5.17%) |
Sep 2, 2026 7w ago | Insider Cluster | $150.37 $142.92 | ▼ −4.96% | ▼ −3.81% | $158.69 (+5.53%) |
Aug 27, 2026 8w ago | Insider Cluster | $145.68 $151.00 | ▲ +3.65% | ▲ +3.54% | $158.69 (+8.93%) |
Aug 21, 2026 9w ago | Insider Cluster | $146.74 $146.34 | ▼ −0.27% | ▼ −0.74% | $158.69 (+8.14%) |
Aug 18, 2026 9w ago | Insider Cluster | $147.60 $148.09 | ▲ +0.33% | ▲ +0.72% | $158.69 (+7.51%) |
Aug 18, 2026 10w ago | Court Ruling | $147.60 $148.09 | ▲ +0.33% | ▲ +0.72% | $158.69 (+7.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers